Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation d'un supplément capillaire oral pour améliorer la force des cheveux et soutenir la croissance chez les femmes et les hommes

10 novembre 2026 mis à jour par: Nutraceutical Wellness Inc.

A Single-Center Prospective Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men With Self-Perceived Hair Thinning

A single-center, open-label, prospective study to demonstrate the efficacy of an oral supplement to improve the strength and support the growth of thinning hair in men and women with self-perceived hair thinning.

Aperçu de l'étude

Description détaillée

Female and male subjects will be enrolled in this single-site, open-label, prospective, interventional study evaluating 5 treatment regimens to improve the appearance of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 50 subjects will be enrolled into each of the 5 supplement groups. Subjects will undergo a baseline, 90 day, and 180 day visit and will have compliance phone calls at Days 45 and 135. Study assessments will include a dermatologist investigator hair assessment, a hair pull test, light microscope hair shaft diameter assessment, and a subject questionnaire.

Type d'étude

Interventionnel

Inscription (Réel)

250

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • North Carolina
      • High Point, North Carolina, États-Unis, 27262
        • Dermatology Consulting Services

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 70 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Female or male subjects with concerns and/or signs of hair thinning.
  2. The subjects must meet the age characteristics based on their supplement group assignment.
  3. Subjects are Fitzpatrick Skin Types I to VI.
  4. Subjects must be in good general health.
  5. Subjects must be classified with thinning hair by the study dermatologist.
  6. Willing to maintain the same hair length, hairstyle, and coloring practices for the duration of the study. Subjects who have color-treated hair must have the color treatment performed at the same time interval prior to each visit.
  7. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  8. Willing and able to adhere to the same dietary lifestyles for the duration of the study
  9. Subjects must express willingness to cooperate with the investigator and comply to study requirements.
  10. Subjects must demonstrate the ability to read and understand all the items in the informed consent document.
  11. Subjects must agree not to use any other hair supplements or start a new vitamin supplement during the study.
  12. Subject has signed an Informed Consent Form in compliance with 21CFR Part 50: "Protection of Human Subjects."
  13. Subject is dependable and able to follow directions and is willing to comply with the schedule of visits.

Exclusion Criteria:

  1. Any previous or current acute or chronic medical or hair condition, which in the investigator's opinion, may interfere with the study results or increase the study participation risks to the subject.
  2. Subjects possessing signs of severe female or male pattern hair loss or alopecia (including androgenetic and traction alopecia) as determined by the study dermatologist.
  3. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  4. Subjects who are not willing to use only the assigned oral study supplement and no new oral supplements during the study.
  5. Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study product.
  6. Subjects, who are pregnant, breast feeding, or planning a pregnancy.
  7. Subjects with clinically significant unstable medical disorders.
  8. Subjects who are unwilling or unable to comply with the requirements of the protocol.
  9. Subjects who have history of a psychological illness or condition that would interfere with their ability to understand and/or follow the requirements of the study.
  10. Subjects with any planned surgeries and/or invasive medical procedures during the course of the study.
  11. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  12. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  13. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
  14. hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  15. History of burning, flaking, itching, and stinging of the scalp.
  16. Utilization of low-level lasers for hair growth in the last three months.
  17. Known history or recent blood work indicating iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Nutrafol Hair Growth Supplement

5 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44.

Hair growth supplement for women ages 45 - 70.

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for men ages 25 - 50.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in hair shaft diameter compared to baseline at Day 180.
Délai: 180 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 180 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

180 days
Change in hair shaft diameter compared to baseline at Day 90.
Délai: 90 days

The ability of an oral supplement to improve hair shaft strength as evidenced by change in hair shaft diameter from baseline at Day 90 in new scalp hair growth as viewed by the study dermatologist under a light microscope in men and women with self-perceived thinning hair.

90 days

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in broken hairs recovered from the hair pull test compared to baseline at Day 180
Délai: 180 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 180 compared to baseline in men and women with self-perceived thinning hair.

180 days
Change in broken hairs recovered from the hair pull test compared to baseline at Day 90
Délai: 90 days

The ability of an oral supplement to improve hair strength as evidenced by a change in the number of broken hairs recovered from the hair pull test at Day 90 compared to baseline in men and women with self-perceived thinning hair.

90 days
Change in hair breakage during the hair pull test compared to baseline at Day 180
Délai: 180 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 180.

180 Days
Change in hair breakage during the hair pull test compared to baseline at Day 90
Délai: 90 Days

The ability of an oral supplement to promote longer hair as evidenced by change in hair breakage observed in the hair pull test compared to baseline at Day 90.

90 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 180
Délai: 180 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 180 in men and women with self-perceived thinning hair.

180 Days
Change in the number of hairs recovered from the hair pull test compared to baseline at Day 90
Délai: 90 Days

The ability of an oral supplement to improve hair shedding as evidenced by a change in the number of hairs recovered from the hair pull test compared to baseline at Day 90 in men and women with self-perceived thinning hair.

90 Days
Subject Self-Perceived Improvement in Hair Quality at Day 180
Délai: 180 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 180.

180 Days
Subject Self-Perceived Improvement in Hair Quality at Day 90
Délai: 90 Days

The ability of an oral supplement to improve hair growth and quality in men and women with self-perceived thinning hair as measured by self-assessment questionnaires using a 5-point ordinal scale (0=excellent, 1=good, 2=average, 3=poor, 4=very poor) at Day 90.

90 Days

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 mai 2024

Achèvement primaire (Réel)

18 février 2025

Achèvement de l'étude (Réel)

18 février 2025

Dates d'inscription aux études

Première soumission

8 avril 2024

Première soumission répondant aux critères de contrôle qualité

11 avril 2024

Première publication (Réel)

12 avril 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner